Springfield, MO

Log in Subscribe

Novartis bets $9.7B on cholesterol drug

Posted online

Novartis AG penned a $9.7 billion purchase deal for Medicines Co.

Bloomberg reports the acquisition focuses mostly on a single treatment: experimental cholesterol drug inclisiran.

Similarly, last year Novartis gained muscle disease gene therapy Zolgensma by buying drugmaker AveXis Inc. for $8.7 billion.

Read more from Bloomberg.


No comments on this story |
Please log in to add your comment
Editors' Pick
Open for Business: Summit Athletix

A construction industry veteran branched out to a new kind of venture with the May 14 opening of Summit Athletix; the newest marijuana dispensary for Flora Farms LLC opened; and Liora’s Original Creations Nail Salon launched.

Most Read
Update cookies preferences